Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer

IMPORTANCE: Combining conventional chemotherapy with targeted therapy has been proposed to improve the pathologic complete response (pCR) rate in patients with inflammatory breast cancer (IBC). Epidermal growth factor receptor (EGFR) expression is an independent predictor of low overall survival in...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:JAMA Oncol
Päätekijät: Matsuda, Naoko, Wang, Xiaoping, Lim, Bora, Krishnamurthy, Savitri, Alvarez, Ricardo H., Willey, Jie S., Parker, Charla A., Song, Juhee, Shen, Yu, Hu, Jianhua, Wu, Wenhui, Li, Nan, Babiera, Gildy V., Murray, James L., Arun, Banu K., Brewster, Abenaa M., Reuben, James M., Stauder, Michael C., Barnett, Chad M., Woodward, Wendy A., Le-Petross, H. T. Carisa, Lucci, Anthony, DeSnyder, Sarah M., Tripathy, Debu, Valero, Vicente, Ueno, Naoto T.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Medical Association 2018
Aiheet:
Original Investigation
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6143003/
https://ncbi.nlm.nih.gov/pubmed/29879283
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2018.1436
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia